Logo image of DERM

JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis

NASDAQ:DERM - Nasdaq - US48115J1097 - Common Stock - Currency: USD

7.93  +0.36 (+4.76%)

Fundamental Rating

3

Overall DERM gets a fundamental rating of 3 out of 10. We evaluated DERM against 193 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. DERM has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DERM had negative earnings in the past year.
In the past year DERM has reported a negative cash flow from operations.
In the past 5 years DERM reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

DERM has a Return On Assets of -9.77%. This is in the better half of the industry: DERM outperforms 68.39% of its industry peers.
Looking at the Return On Equity, with a value of -38.55%, DERM is in line with its industry, outperforming 57.51% of the companies in the same industry.
Industry RankSector Rank
ROA -9.77%
ROE -38.55%
ROIC N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

With a decent Gross Margin value of 60.39%, DERM is doing good in the industry, outperforming 69.95% of the companies in the same industry.
In the last couple of years the Gross Margin of DERM has declined.
The Profit Margin and Operating Margin are not available for DERM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DERM has more shares outstanding
The number of shares outstanding for DERM has been increased compared to 5 years ago.
DERM has a worse debt/assets ratio than last year.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.15, we must say that DERM is in the distress zone and has some risk of bankruptcy.
DERM has a Altman-Z score (0.15) which is in line with its industry peers.
DERM has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
DERM has a Debt to Equity ratio of 1.16. This is in the lower half of the industry: DERM underperforms 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Altman-Z 0.15
ROIC/WACCN/A
WACC10.21%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

DERM has a Current Ratio of 1.34. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of DERM (1.34) is worse than 73.06% of its industry peers.
DERM has a Quick Ratio of 1.03. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
DERM has a Quick ratio of 1.03. This is in the lower half of the industry: DERM underperforms 73.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.03
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DERM have decreased strongly by -378.57% in the last year.
Looking at the last year, DERM shows a very negative growth in Revenue. The Revenue has decreased by -29.69% in the last year.
DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.96% yearly.
EPS 1Y (TTM)-378.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
Revenue 1Y (TTM)-29.69%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%0.84%

3.2 Future

DERM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.20% yearly.
The Revenue is expected to grow by 39.80% on average over the next years. This is a very strong growth
EPS Next Y74.33%
EPS Next 2Y69.56%
EPS Next 3Y59.2%
EPS Next 5YN/A
Revenue Next Year25.14%
Revenue Next 2Y38.2%
Revenue Next 3Y39.8%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.89, the valuation of DERM can be described as reasonable.
Based on the Price/Forward Earnings ratio, DERM is valued cheaper than 86.01% of the companies in the same industry.
DERM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.09.
Industry RankSector Rank
PE N/A
Fwd PE 8.89
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

DERM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DERM's earnings are expected to grow with 59.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.56%
EPS Next 3Y59.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DERM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOURNEY MEDICAL CORP

NASDAQ:DERM (8/11/2025, 3:29:42 PM)

7.93

+0.36 (+4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners27.8%
Inst Owner Change-3.91%
Ins Owners11.46%
Ins Owner Change0.64%
Market Cap137.19M
Analysts82
Price Target10.54 (32.91%)
Short Float %9.34%
Short Ratio7.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.99%
Min EPS beat(2)25.7%
Max EPS beat(2)58.28%
EPS beat(4)2
Avg EPS beat(4)13.68%
Min EPS beat(4)-16.28%
Max EPS beat(4)58.28%
EPS beat(8)4
Avg EPS beat(8)62.66%
EPS beat(12)4
Avg EPS beat(12)28.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-6.06%
Max Revenue beat(2)6.86%
Revenue beat(4)2
Avg Revenue beat(4)1.35%
Min Revenue beat(4)-6.06%
Max Revenue beat(4)6.86%
Revenue beat(8)4
Avg Revenue beat(8)13.71%
Revenue beat(12)4
Avg Revenue beat(12)4.31%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.98%
PT rev (3m)4.64%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)6.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.89
P/S 2.44
P/FCF N/A
P/OCF N/A
P/B 6.37
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)0.89
Fwd EY11.25%
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS3.25
BVpS1.25
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.77%
ROE -38.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.39%
FCFM N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score2
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.03
Altman-Z 0.15
F-Score2
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-378.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
EPS Next Y74.33%
EPS Next 2Y69.56%
EPS Next 3Y59.2%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.69%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%0.84%
Revenue Next Year25.14%
Revenue Next 2Y38.2%
Revenue Next 3Y39.8%
Revenue Next 5YN/A
EBIT growth 1Y-2199.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year143.94%
EBIT Next 3Y84.08%
EBIT Next 5YN/A
FCF growth 1Y-7.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.85%
OCF growth 3YN/A
OCF growth 5YN/A